Adaptive Biotechnologies

The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ, uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. immunoSEQ was launched in September 2010 and has a worldwide customer base.

Type
Private
HQ
Seattle, US
Founded
2009
Employees
222 (est)+2%
Adaptive Biotechnologies was founded in 2009 and is headquartered in Seattle, US

Key People at Adaptive Biotechnologies

Sean Nolan

Sean Nolan

Chief Technology Officer
Nancy Hill

Nancy Hill

Senior Vice President of Commercial Operations
Chad Robins

Chad Robins

President, Chief Executive Officer and Co-founder
Harlan Robins

Harlan Robins

Chief Scientific Officer, Co-founder
Chad Cohen

Chad Cohen

Chief Financial Officer
Kathleen Determann

Kathleen Determann

Vice President and General Counsel

Adaptive Biotechnologies Locations

Seattle, US
South San Francisco, US

Adaptive Biotechnologies Metrics

Adaptive Biotechnologies Summary

Founding Date

2009

Total Funding

$402 M

Latest funding size

$195 M

Time since last funding

over 1 year

Investors

Adaptive Biotechnologies's latest funding round of $195 M was in May 2015. In total, Adaptive Biotechnologies has raised $402 M.

Adaptive Biotechnologies Online Presence

Adaptive Biotechnologies News

Adaptive Biotechnologies Company Life

You may also be interested in